Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Inovio Pharma

Start price
Target price
Perf. (%)
€9.25
-
-2.703%

Risky Investment
Citigroup Inc.

Start price
Target price
Perf. (%)
€36.88
-
0.271%

Revenue growth >5% per year expected
EBIT growth >5% per year expected
High dividend yield expected
Deutsche Börse AG

Start price
Target price
Perf. (%)
€136.05
-
-0.809%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Deutsche Bank AG

Start price
Target price
Perf. (%)
€7.98
€9.00
2.932%

Risky Investment
Deutsche Bank AG

Start price
Target price
Perf. (%)
€7.98
€9.00
2.932%

Risky Investment
Intel Corp.

Start price
Target price
Perf. (%)
€40.50
-
-0.272%

Intel Corp.

Start price
Target price
Perf. (%)
€40.50
-
-0.272%

Intel Corp.

Start price
Target price
Perf. (%)
€40.50
-
-0.272%

Intel Corp.

Start price
Target price
Perf. (%)
€40.50
-
-0.272%

Tesla Inc

Start price
Target price
Perf. (%)
€347.00
€310.00
0.648%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Tesla Inc

Start price
Target price
Perf. (%)
€347.00
€310.00
0.648%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Bayer AG

Start price
Target price
Perf. (%)
€42.35
€48.00
1.358%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Bayer AG

Start price
Target price
Perf. (%)
€42.35
€48.00
1.358%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.61
€55.00
-6.354%

Known brand
Probably not worthwhile Investment
Significant cyclical dependencies
Revenue decline/stagnation expected
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.61
€55.00
-6.354%

Known brand
Probably not worthwhile Investment
Significant cyclical dependencies
Revenue decline/stagnation expected
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.61
€55.00
-6.354%

Known brand
Probably not worthwhile Investment
Significant cyclical dependencies
Revenue decline/stagnation expected
Leggett & Platt Inc.

Start price
Target price
Perf. (%)
€37.31
-
-0.201%

EBIT growth >5% per year expected
High dividend yield expected
Revenue growth >5% per year expected
Thermo Fisher Scientific Inc.

Start price
Target price
Perf. (%)
€406.60
€420.00
-0.812%

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
MGM Resorts International

Start price
Target price
Perf. (%)
€18.70
-
3.743%

Undervalued
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Future proof or reliable business model
Sunrun Inc

Start price
Target price
Perf. (%)
€48.14
€60.00
-1.704%

Emcore Corp.

Start price
Target price
Perf. (%)
€3.06
€4.38
1.307%

Misonix Inc.

Start price
Target price
Perf. (%)
€10.30
€12.00
0.971%

Could be worthwhile Investment >10% per year
Roku

Start price
Target price
Perf. (%)
€184.70
€218.00
1.830%

Mastercard Inc. A

Start price
Target price
Perf. (%)
€283.50
€300.00
-2.610%

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
High dividend yield expected
Future proof or reliable business model
Microsoft Corp.

Start price
Target price
Perf. (%)
€183.54
€200.00
-1.340%

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation